BACKGROUND & AIMS: Cholangiocarcinomas appear to arise from the malignant transformation of cholangiocytes lining the biliary tract. Because the development of an in vitro model of malignant transformation can provide a powerful new tool for establishing critical events governing the molecular pathogenesis of cholangiocarcinoma, we investigated the potential of achieving malignant transformation of cultured rat cholangiocytes in relation to aberrant overexpression of mutationally activated erbB-2/neu. METHODS: Malignant neoplastic transformation was achieved after infection of the rat cholangiocyte cell line, designated BDE1, with the retrovirus Glu664-neu, containing the transforming rat erbB-2/neu oncogene. RESULTS: Compared with untransformed control cells, malignant transformants carrying the activating erbB-2/neu mutation prominently overexpressed p185neu receptor protein, which was phosphorylated strongly at its major autophosphorylation site at tyrosine 1248. Moreover, erbB-2/neu transformation of BDE1 cells resulted in increased telomerase activity, up-regulation of cyclooxygenase-2 with overproduction of prostaglandin E(2), enhanced phosphorylation of mitogen-activated protein kinase and of serine/threonine kinase Akt/PKB, overexpression of vascular endothelial growth factor, and increased mucin 1 messenger RNA expression. Only erbB-2/neu transformants were tumorigenic when transplanted into isogeneic rats, yielding a 100% incidence of tumors closely resembling human desmoplastic ductal cholangiocarcinomas in their morphology. Malignant cholangiocytes in the tumors were strongly immunoreactive for biliary cytokeratin 19, p185neu, and cyclooxygenase-2. CONCLUSIONS: This unique malignant transformation model recapitulates key molecular features of the human disease and appears to be well suited for testing novel molecular therapeutic strategies against cholangiocarcinoma.
BACKGROUND & AIMS:Cholangiocarcinomas appear to arise from the malignant transformation of cholangiocytes lining the biliary tract. Because the development of an in vitro model of malignant transformation can provide a powerful new tool for establishing critical events governing the molecular pathogenesis of cholangiocarcinoma, we investigated the potential of achieving malignant transformation of cultured rat cholangiocytes in relation to aberrant overexpression of mutationally activated erbB-2/neu. METHODS: Malignant neoplastic transformation was achieved after infection of the rat cholangiocyte cell line, designated BDE1, with the retrovirus Glu664-neu, containing the transforming raterbB-2/neu oncogene. RESULTS: Compared with untransformed control cells, malignant transformants carrying the activating erbB-2/neu mutation prominently overexpressed p185neu receptor protein, which was phosphorylated strongly at its major autophosphorylation site at tyrosine 1248. Moreover, erbB-2/neu transformation of BDE1 cells resulted in increased telomerase activity, up-regulation of cyclooxygenase-2 with overproduction of prostaglandin E(2), enhanced phosphorylation of mitogen-activated protein kinase and of serine/threonine kinase Akt/PKB, overexpression of vascular endothelial growth factor, and increased mucin 1 messenger RNA expression. Only erbB-2/neu transformants were tumorigenic when transplanted into isogeneic rats, yielding a 100% incidence of tumors closely resembling humandesmoplastic ductal cholangiocarcinomas in their morphology. Malignant cholangiocytes in the tumors were strongly immunoreactive for biliary cytokeratin 19, p185neu, and cyclooxygenase-2. CONCLUSIONS: This unique malignant transformation model recapitulates key molecular features of the human disease and appears to be well suited for testing novel molecular therapeutic strategies against cholangiocarcinoma.
Authors: Christian D Fingas; Joachim C Mertens; Nataliya Razumilava; Steven F Bronk; Alphonse E Sirica; Gregory J Gores Journal: Liver Int Date: 2011-12-02 Impact factor: 5.828
Authors: Martina Šrajer Gajdošik; Douglas C Hixson; Kate E Brilliant; DongQin Yang; Monique E De Paepe; Djuro Josić; David R Mills Journal: Exp Mol Pathol Date: 2018-05-29 Impact factor: 3.362
Authors: Miguel Á Manzanares; Akihiro Usui; Deanna J Campbell; Catherine I Dumur; Gabrielle T Maldonado; Michel Fausther; Jonathan A Dranoff; Alphonse E Sirica Journal: Am J Pathol Date: 2017-03-15 Impact factor: 4.307
Authors: Michael R O'Dell; Jing Li Huang; Christa L Whitney-Miller; Vikram Deshpande; Paul Rothberg; Valerie Grose; Randall M Rossi; Andrew X Zhu; Hartmut Land; Nabeel Bardeesy; Aram F Hezel Journal: Cancer Res Date: 2012-01-20 Impact factor: 12.701
Authors: Christian D Fingas; Boris R A Blechacz; Rory L Smoot; Maria E Guicciardi; Justin Mott; Steve F Bronk; Nathan W Werneburg; Alphonse E Sirica; Gregory J Gores Journal: Hepatology Date: 2010-08 Impact factor: 17.425
Authors: Nataliya Razumilava; Sergio A Gradilone; Rory L Smoot; Joachim C Mertens; Steven F Bronk; Alphonse E Sirica; Gregory J Gores Journal: J Hepatol Date: 2013-11-14 Impact factor: 25.083
Authors: Sergio A Gradilone; Brynn N Radtke; Pamela S Bogert; Bing Q Huang; Gabriella B Gajdos; Nicholas F LaRusso Journal: Cancer Res Date: 2013-01-31 Impact factor: 12.701